المؤلفون: Chorão, Pedro, Montoro, Juan, Balaguer-Roselló, Aitana, Guerreiro, Manuel, Villalba, Marta, Facal, Ana, Solves, Pilar, Gómez-Segui, Inés, Pasquini, Marcelo C., Granados, Pablo, Bataller, Ana, Louro, Alberto, de la Rubia, Javier, Sanz, Miguel A., Sanz, Jaime

المصدر: Transplantation and Cellular Therapy ; volume 29, issue 5, page 322.e1-322.e5 ; ISSN 2666-6367

مصطلحات موضوعية: Transplantation, Cell Biology, Hematology, Molecular Medicine, Immunology and Allergy

الإتاحة: https://doi.org/10.1016/j.jtct.2023.01.016Test
https://api.elsevier.com/content/article/PII:S2666636723000374?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2666636723000374?httpAccept=text/plainTest

المؤلفون: Chorão, Pedro, Henriques, Marta, Villalba, Marta, Montoro, Juan, Balaguer-Roselló, Aitana, González, Eva María, Gómez, María Dolores, Gómez, Inés, Solves, Pilar, Santiago, Marta, Asensi, Pedro, Lamas, Brais, Bataller, Ana, Granados, Pablo, Eiris, Juan, Martínez, David, Louro, Alberto, Rebollar, Paula, Perla, Aurora, Salavert, Miguel, de la Rubia, Javier, Sanz, Miguel Ángel, Sanz, Jaime

المصدر: Transplantation and Cellular Therapy; May 2024, Vol. 30 Issue: 5 p538.e1-538.e10, 48430p

مستخلص: • First CMV reactivations in HSCT with PTCy without letermovir prophylaxis occurred in 46% of patients.• The reactivation rate was 73% for CMV seropositive recipients and 49% for CMV-seropositive donors.• Risk factors for reactivation were CMV seropositivity, haploidentical HSCT, older patient, and grade II-IV acute GVHD.• Second and third CMV reactivations occurred in 13% and 4.4% of patients, independent of donor type.

المؤلفون: Sanz, Miguel Ángel, Montoro, Juan, Balaguer-Roselló, Aitana, Chorão, Pedro, Villalba, Marta, Gómez, Inés, Solves, Pilar, Santiago, Marta, Asensi, Pedro, Lamas, Brais, Bataller, Ana, Granados, Pablo, Eiris, Juan, Martinez, David, Lloret, Pilar, Louro, Alberto, Rebollar, Paula, Perla, Aurora, de la Rubia, Javier, Sanz, Jaime

المصدر: Bone Marrow Transplant ; ISSN:1476-5365

الوصف: This 45-year study (1978-2022) at a single institution evaluated HSCT outcomes and complications, emphasizing recent advances, with to provide insights into HSCT's evolving field and ongoing efforts to enhance patient outcomes. Involving 1707 patients, the study revealed an initial phase (1978-1987) with a limited activity that yielded modest outcomes, a nearly three-decade span (1988-2016) with a substantial increase in transplant activity, emphasizing umbilical cord blood transplantation (UCBT) for patients lacking a suitable matched sibling donor. In addition to a gradual increase in recipient age, significant improvement in outcomes emerged in the recent period (2017-2022), marked by UCBT replacement with haploidentical transplants, introduction of PTCY-based GVHD prophylaxis for all type of transplants, and increased use of conditioning regimens with thiotepa, busulfan, and fludarabine. In this period, reductions in GVHD, non-relapse mortality, and relapse rates significantly contributed to improved overall survival, event-free survival, and GVHD-free/relapse-free survival. The study identified specific factors, including GVHD prophylaxis and donor selection changes, associated with these positive trends. This four-decade study provides a unique perspective on allogeneic HSCT, showcasing the dynamic evolution of transplantation practices and their impact on outcomes, offering valuable insights for personalized treatment approaches and emphasizing continual innovation in this critical therapeutic modality.

العلاقة: https://doi.org/10.1038/s41409-024-02319-xTest; https://pubmed.ncbi.nlm.nih.gov/38918495Test

الإتاحة: https://doi.org/10.1038/s41409-024-02319-xTest
https://pubmed.ncbi.nlm.nih.gov/38918495Test

المؤلفون: Lazzari, Lorenzo, Balaguer-Roselló, Aitana, Montoro, Juan, Greco, Raffaella, Hernani Morales, Rafael, Lupo-Stanghellini, Maria Teresa, Villalba, Marta, Giglio, Fabio, Facal, Ana, Lorentino, Francesca, Guerreiro, Manuel, Bruno, Alessandro, Pérez, Ariadna, Xue, Elisabetta, Clerici, Daniela, Piemontese, Simona, Piñana, José Luis, Sanz, Miguel Ángel, Solano Vercet, Carlos, de la Rubia Comos, Javier, Ciceri, Fabio, Peccatori, Jacopo, Sanz, Jaime

مصطلحات موضوعية: Patologia

الوصف: Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from HLA-matched sibling donor, 101 (42%) from HLA-matched and mismatched unrelated donor, and 64 (26%) from haploidentical donor. Except for neutrophil and platelet engraftment, which was slower in the haploidentical cohort, no significant differences were observed in major transplant outcomes according to donor type in univariate and multivariate analysis. GvHD prophylaxis with Sir-PTCy, with or without MMF, is safe and effective in patients with AML undergoing myeloablative allo-HSCT, resulting in low rates of transplant-related mortality, relapse/progression, and acute and chronic GvHD in all donor settings.

وصف الملف: application/pdf

العلاقة: Bone Marrow Transplantation, 2022; Lazzari, Lorenzo Balaguer-Roselló, Aitana Montoro, Juan Greco, Raffaella Hernani Morales, Rafael Lupo-Stanghellini, Maria Teresa Villalba, Marta Giglio, Fabio Facal, Ana Lorentino, Francesca Guerreiro, Manuel Bruno, Alessandro Pérez, Ariadna Xue, Elisabetta Clerici, Daniela Piemontese, Simona Piñana, Jose Luis Sanz, Miguel Ángel Solano Vercet, Carlos de la Rubia Comos, Javier Ciceri, Fabio Peccatori, Jacopo Sanz, Jaime 2022 Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia Bone Marrow Transplantation; https://hdl.handle.net/10550/83733Test; 154548

الإتاحة: https://doi.org/10.1038/s41409-022-01725-3Test
https://hdl.handle.net/10550/83733Test

المؤلفون: Montoro, Juan, Balaguer-Roselló, Aitana, Sanz, Jaime

المصدر: Current Opinion in Oncology; Nov2023, Vol. 35 Issue 6, p564-573, 10p

المؤلفون: Hernani, Rafael, Piñana, José Luis, Pérez, Ariadna, Quintero, Abdiel, Montoro, Juan, Hernández‐Boluda, Juan C., Carretero, Carlos, Balaguer‐Roselló, Aitana, Guerreiro, Manuel, Lorenzo, Ignacio, Aguilar, Cristóbal, Giménez, Estela, Navarro, David, Sanz, Miguel A., Sanz, Jaime, Solano, Carlos

المصدر: eJHaem ; volume 2, issue 2, page 236-248 ; ISSN 2688-6146 2688-6146

الوصف: Sirolimus has emerged as an alternative to calcineurin inhibitors‐based (CNI) graft‐versus‐host disease (GVHD) prophylaxis. This retrospective study compares the outcome of 133 consecutive adult patients with haematological malignancies undergoing haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCy) and mycophenolate mofetil (MMF), combined with cyclosporine A (PTCy–CsA–MMF, n = 67) or sirolimus (PTCy–Sir–MMF, n = 66) as GVHD prophylaxis strategy. The median follow‐up was 48 (range 22–83) and 13 (range 3–33) months, respectively. PTCy–CsA–MMF was associated in multivariate analyses with a higher risk of acute kidney injury (HR 2.1, 95% CI, 1.21–3.57, p = .008) and thrombotic microangiopathy (HR 12.5, 95% CI, 1.66–93.5, p = .014), whereas PTCy–Sir–MMF was associated with a higher risk of hepatic sinusoidal obstruction syndrome (SOS) (HR 10.8, 95% CI, 1.52–77, p = .018), especially late‐onset forms, which totally resolved and none of the patients needed discontinuation of sirolimus. Two SOS‐related deaths were detected, both in the PTCy–CsA–MMF subgroup. Both GVHD prophylaxis strategies were otherwise comparable in terms of engraftment, GVHD incidence and survival.

الإتاحة: https://doi.org/10.1002/jha2.183Test

المؤلفون: Guerreiro, Manuel, Aguilar‐Gallardo, Cristóbal, Montoro, Juan, Francés‐Gómez, Clara, Latorre, Víctor, Luna, Irene, Planelles, Dolores, Carrasco, María Paz, Gómez, María Dolores, González‐Barberá, Eva María, Aguado, Cristina, Sempere, Amparo, Solves, Pilar, Gómez‐Seguí, Inés, Balaguer‐Rosello, Aitana, Louro, Alberto, Perla, Aurora, Larrea, Luis, Sanz, Jaime, Arbona, Cristina, de la Rubia, Javier, Geller, Ron, Sanz, Miguel Ángel, Sanz, Guillermo, Luis Piñana, José

المساهمون: Fundación General CSIC

المصدر: Transplant Infectious Disease ; volume 23, issue 4 ; ISSN 1398-2273 1399-3062

الوصف: Cellular and humoral response to acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections is on focus of research. We evaluate herein the feasibility of expanding virus‐specific T cells (VST) against SARS‐CoV‐2 ex vivo through a standard protocol proven effective for other viruses. The experiment was performed in three different donors' scenarios: (a) SARS‐CoV‐2 asymptomatic infection/negative serology, (b) SARS‐CoV‐2 symptomatic infection/positive serology, and (c) no history of SARS‐CoV‐2 infection/negative serology. We were able to obtain an expanded VST product from donors 1 and 2 (1.6x and 1.8x increase of baseline VST count, respectively) consisting in CD3 + cells (80.3% and 62.7%, respectively) with CD4 + dominance (60% in both donors). Higher numbers of VST were obtained from the donor 2 as compared to donor 1. T‐cell clonality test showed oligoclonal reproducible peaks on a polyclonal background for both donors. In contrast, VST could be neither expanded nor primed in a donor without evidence of prior infection. This proof‐of‐concept study supports the feasibility of expanding ex vivo SARS‐CoV‐2‐specific VST from blood of convalescent donors. The results raise the question of whether the selection of seropositive donors may be a strategy to obtain cell lines enriched in their SARS‐CoV‐2‐specificity for future adoptive transfer to immunosuppressed patients.

الإتاحة: https://doi.org/10.1111/tid.13602Test

المؤلفون: De la Puerta, Rosalía, Montoro, Juan, Aznar, Carla, Lorenzo, Ignacio, González-Barberá, Eva María, Balaguer-Roselló, Aitana, Guerreiro, Manuel, Domínguez, Lara, Salavert, Miguel, Aguilar, Cristóbal, de la Rubia, Javier, Sanz, Jaime, Gómez, María Dolores, Piñana, José Luis

المصدر: Bone Marrow Transplantation ; volume 56, issue 9, page 2212-2220 ; ISSN 0268-3369 1476-5365

مصطلحات موضوعية: Transplantation, Hematology

الإتاحة: https://doi.org/10.1038/s41409-021-01319-5Test
https://www.nature.com/articles/s41409-021-01319-5.pdfTest
https://www.nature.com/articles/s41409-021-01319-5Test

المؤلفون: Romero, Samuel, Balaguer-Roselló, Aitana, Montoro, Juan, Beneit, Paola, Martínez, Amelia, Ruiz, Cristina, Andreu, Rafael, Guerreiro, Manuel, Arnao, Mario, Montava, Alberto, Vicente, Ana I., Jarque, Isidro, Sanz, Jaime

المصدر: Therapeutic Advances in Hematology ; volume 12, page 204062072110381 ; ISSN 2040-6207 2040-6215

مصطلحات موضوعية: Hematology

الوصف: The poor prognosis of refractory or relapsed (R/R) classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation has improved greatly due to the introduction of brentuximab vedotin and PD-1 inhibitors. However, the duration of response achieved with these novel agents is too short. The information about the management of patients after anti-PD-1 therapy failure is very limited in cHL, although chemotherapy alone or combined with PD-1 inhibitors has shown encouraging results. We report three cases of heavily pretreated cHL, refractory to nivolumab monotherapy, successfully rescued with the addition of chemotherapy to nivolumab, as a bridge to allogeneic stem cell transplantation (allo-SCT). All three patients presented poor clinical features such as three to four previous lines including brentuximab vedotin and autologous stem cell transplantation, refractoriness to the last line of therapy previous to nivolumab, and rapid disease progression. Notwithstanding these characteristics and nivolumab failure, they achieved a complete response after the addition of chemotherapy, were consolidated with allo-SCT, and still remain in complete response. There are few studies concerning the combination of PD-1 inhibitors and chemotherapy after nivolumab failure, including one retrospective study and one phase II trial with nivolumab plus bendamustine. Therefore, only few patients are consolidated with allo-SCT. However, there are several ongoing trials investigating new combinations of chemotherapy and PD-1 inhibitors in R/R cHL, as well as in first line. All these data suggest that anti-PD-1 therapy may reprogram the immune system, activating and inhibiting effector and immunosuppressive cells, respectively, leading to overtake of chemorefractoriness. Allo-SCT can increase the immune-related events of patients treated with anti-PD-1 previously, consistent on acute graft- versus-host disease, sinusoidal obstruction syndrome, and noninfectious febrile syndrome. In conclusion, the combination of PD-1 inhibitor ...

الإتاحة: https://doi.org/10.1177/20406207211038181Test

المؤلفون: Balaguer-Rosello, Aitana, Piñana, José Luis, Bataller, Luis, Montoro, Juan, Romero, Samuel, Navarro, Irene, Lorenzo, Ignacio, Andreu, Rafael, Guerreiro, Manuel, Aguilar, Cristobal, Gorriz, David, Dominguez, Lara, de la Puerta, Rosalia, Gómez, Inés, Solves, Pilar, Jarque, Isidro, Sanz, Miguel Ángel, Sanz, Guillermo, Sanz, Jaime

المصدر: Transplantation and Cellular Therapy ; volume 27, issue 3, page 261.e1-261.e7 ; ISSN 2666-6367

مصطلحات موضوعية: Transplantation, Cell Biology, Hematology, Molecular Medicine, Immunology and Allergy

الإتاحة: https://doi.org/10.1016/j.jtct.2020.12.019Test
https://api.elsevier.com/content/article/PII:S2666636720300932?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2666636720300932?httpAccept=text/plainTest